Accepted for/Published in: JMIR Formative Research
Date Submitted: Aug 5, 2022
Date Accepted: Oct 14, 2022
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Does Insurance Type Matter on the Computer Too? Comparing Outcomes for Youth with Public v Private Health Insurance Attending a Telehealth Intensive Outpatient Program: A Quality Improvement Analysis
ABSTRACT
Background:
COVID-19 exacerbated a growing mental health crisis among youth and young adults, made worse by a lack of existing in-person options for high-acuity care. The emergence and growth of remote intensive outpatient programs (IOP) is one solution to overcoming geographic limitations to care. However, it is still unclear whether remote IOP engenders equivalent clinical outcomes among youth with public insurance (e.g., Medicaid) versus private insurance (e.g., commercial), given the disparities found in previous research of place-based treatment in both clinical and engagement outcomes.
Objective:
The analysis upon which the following report is based sought to establish, as part of ongoing quality improvement efforts, whether engagement and clinical outcomes among adolescents and young adults attending remote IOP treatment differed between those with public versus private insurance. Identification of disparities by payor type were used to inform programmatic decisions within the remote IOP system for which this quality improvement analysis was conducted.
Methods:
Pearson’s chi-square analyses and independent t-tests were used to establish that the two groups defined by insurance type were equivalent on clinical outcomes (depression, suicidal ideation, non-suicidal self-injury) at intake and to compare change in clinical outcomes. McNemar’s chi-square analysis and repeated-measures t-tests were used to assess changes in clinical outcomes between intake and discharge in the sample as a whole. A total of N=495 clients who attended the remote IOP for youth and young adults in 14 states, who participated in seven or more treatment sessions and who completed both intake and discharge surveys between July 2021 and April 2022 were included in analysis.
Results:
Overall, the youth and young adults in the remote IOP attended 90% of their scheduled group sessions (SD=16.48%) and reported significantly fewer depression symptoms at discharge (t447=12.51, P<.001). McNemar’s chi square tests of change indicated significant reductions from intake to discharge in suicidal ideation (X21, 470=19.2, P<.001), with nearly three quarters of youth who reported suicidal ideation at intake (n=201) no longer reporting it at discharge (n=143), and in NSSI (X21, 430=40.65, P<.001), with more than half of youth reporting NSSI at intake (n=206) reporting lower self−harm at discharge (n=120). No significant differences emerged by insurance type in attendance (Public Mdn=89%, Private Mdn=92%; P=.099), length of stay (t416= −.35, P=.73), or reductions in clinical outcomes [depressive symptom severity (t444= −.87, P=.38), active suicidal ideation (X21, 233=.03, P=.88), NSSI frequency (t426= −.98, p=.33)].
Conclusions:
Findings suggest that remote IOP is a feasible and effective treatment solution for youth and young adults who are struggling with depression, suicidal ideation, and NSSI. Furthermore, when given access to the same accessible, high−acuity care, youth and young adults on both public and private insurance can be engaged in programming at comparable rates and achieve similar improvements in clinical outcomes. Clinical Trial: N/A
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.